BCG (Bacillus Calmette-Guérin) Intravesical Therapy
Treatment for Bladder Cancer
Typical Dosage: 1 vial (50-80 mg) intravesically once a week for 6 weeks, then maintenance
Effectiveness
80%
Safety Score
55%
Clinical Trials
24
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
1 vial (50-80 mg) intravesically once a week for 6 weeks, then maintenance
Time to Effect
3-6 months
Treatment Duration
1-3 years (induction + maintenance)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$4,000
Side Effect Mgmt:$1,500
Total Annual:$20,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$55,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$27,333.33
Cost per Remission
$29,285.71
BCG (Bacillus Calmette-Guérin) Intravesical Therapy Outcomes
for Bladder Cancer
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Remission Rate
+70%
Common Side Effects
Cystitis (bladder inflammation)
+80%
Flu-like symptoms (fever, chills, malaise)
+40%
Urinary frequency/urgency
+70%
Hematuria (blood in urine)
+15%
Sources:
Active Clinical Trials
9 active trials recruiting for BCG (Bacillus Calmette-Guérin) Intravesical Therapy in Bladder Cancer
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
NCT04179162ACTIVE NOT RECRUITINGPHASE1, PHASE2
54 participants
INTERVENTIONAL
Hartford, United States +7 more
Started: Nov 22, 2019
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
NCT03504163ACTIVE NOT RECRUITINGPHASE2
45 participants
INTERVENTIONAL
Basking Ridge, United States +6 more
Started: Jun 27, 2018
A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC.
NCT07064863NOT YET RECRUITINGPHASE1, PHASE2
31 participants
INTERVENTIONAL
Kingston, Canada
Started: Aug 1, 2025
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
NCT04630730ACTIVE NOT RECRUITINGPHASE2
46 participants
INTERVENTIONAL
Baden, Switzerland +9 more
Started: Jun 24, 2022
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
NCT06829823NOT YET RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Started: Nov 1, 2025
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202ACTIVE NOT RECRUITINGPHASE3
1.14K participants
INTERVENTIONAL
Scottsdale, United States +239 more
Started: Mar 23, 2023
BCG for Therapeutic Use Phase Ⅲ Clinical Trial
NCT06747455RECRUITINGPHASE3
438 participants
INTERVENTIONAL
Shanghai, China
Started: Apr 8, 2025
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158RECRUITINGPHASE1, PHASE2
55 participants
INTERVENTIONAL
Phoenix, United States +11 more
Started: Nov 21, 2017
Intravesical Gem/Doce in Patients With NMIBC
NCT05644041RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Tucson, United States
Started: Mar 1, 2023
Completed Clinical Trials
6 completed trials for BCG (Bacillus Calmette-Guérin) Intravesical Therapy in Bladder Cancer
Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer
NCT01442519COMPLETEDPHASE3
212 participants
INTERVENTIONAL
Rome, Italy
Started: Jan 1, 1994
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
NCT02281383COMPLETEDPHASE2
80 participants
INTERVENTIONAL
Basking Ridge, United States +4 more
Started: Oct 1, 2014
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
NCT02311101COMPLETEDPHASE1
18 participants
INTERVENTIONAL
San Antonio, United States
Started: Mar 1, 2012
Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder Cancer
NCT04319263COMPLETEDNA
1.6K participants
INTERVENTIONAL
Al Mansurah, Egypt
Started: Mar 1, 2020
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
NCT04172675COMPLETEDPHASE2
107 participants
INTERVENTIONAL
Tucson, United States +149 more
Started: Feb 28, 2020
Markers of Response to Intravesical Bladder Cancer Therapy
NCT01007058COMPLETED
150 participants
OBSERVATIONAL
Houston, United States
Started: Jun 1, 2005
Showing 20 of 24 total trials